Negative in Ames, in vitro chromosome aberration (human lymphocytes) and in vivo mouse micronucleus assays
“The genotoxic potential of AMX0035 was tested in a standard battery of in vitro (Ames, chromosomal aberration in human lymphocytes) and in vivo (micronucleus in CD-1 mouse) assays, which were adequate and negative.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Carcinogenicity
Not conducted; mouse and rat studies are postmarketing requirements
“Carcinogenicity studies have not been conducted. Carcinogenicity studies in mouse and rat may be conducted post-approval, as agreed to by the Division (Meeting Minutes, April 7, 2020, and July 22, 2021) because of the seriousness of the indication.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
No adverse effects on maternal or offspring health and development in fertility, EFD or PPND studies
“There were no adverse effects on maternal health or offspring health and development in fertility, EFD, or PPND studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 47Source ↗
Safety pharmacology
No CNS study; minipig CV and rat respiratory studies showed no adverse effects
“CNS safety pharmacology was not assessed; however, cardiovascular and respiratory safety pharmacology endpoints were assessed in standalone studies in Gottingen minipig and SD rat, respectively, following administration of 1000 mg/kg PB/333.3 mg/kg TUDCA and did not indicate any adverse effects.”
✓ VerifiedFDA pharmacology/toxicology review, p. 45Source ↗
Genotox: Ames
Negative (phenylbutyrate and TUDCA tested individually)
“PB and TUDCA were individually assessed in Ames and in vitro chromosomal aberration assays and were found to be negative.”
✓ VerifiedFDA pharmacology/toxicology review, p. 46Source ↗
Genotox: in vitro mammalian
Chromosomal aberration in human lymphocytes: negative
“The genotoxic potential of AMX0035 was tested in a standard battery of in vitro (Ames, chromosomal aberration in human lymphocytes) and in vivo (micronucleus in CD-1 mouse) assays, which were adequate and negative.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Genotox: in vivo
Mouse micronucleus: negative up to 2000 mg/kg
“AMX0035 was tested at oral doses up to 2000 mg/kg and found to be negative in an in vivo micronucleus assay in CD mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 46Source ↗
Carcinogenicity model
Not conducted; mouse and rat studies to be done post-approval given seriousness of indication
“Carcinogenicity studies have not been conducted. Carcinogenicity studies in mouse and rat may be conducted post-approval, as agreed to by the Division (Meeting Minutes, April 7, 2020, and July 22, 2021) because of the seriousness of the indication.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Carcinogenicity timing
Mouse and rat carcinogenicity studies not conducted before approval; postmarketing requirements
“If the NDA is approved, carcinogenicity studies in two species (mouse and rat) should be conducted as post-marketing requirements, as previously agreed to by the Division and communicated to the sponsor.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
hERG / QT
Minipig cardiovascular safety pharmacology: no adverse effects
“CNS safety pharmacology was not assessed; however, cardiovascular and respiratory safety pharmacology endpoints were assessed in standalone studies in Gottingen minipig and SD rat, respectively, following administration of 1000 mg/kg PB/333.3 mg/kg TUDCA and did not indicate any adverse effects.”
✓ VerifiedFDA pharmacology/toxicology review, p. 45Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative